Cable Hill Partners’s Ligand Pharmaceuticals LGND Stock Holding History

Cable Hill Partners’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-30	Closed	-$2K	–	446
2019 Q1	$2K	Hold	30	–	–	﹤0.01%	756
2018 Q4	$3K	Hold	30	–	–	﹤0.01%	665
2018 Q3	$5K	Sell	30 -5	-14%	-$754	﹤0.01%	571
2018 Q2	$5K	Hold	35	–	–	﹤0.01%	664
2018 Q1	$3K	Sell	35 -60	-63%	-$5.93K	﹤0.01%	775
2017 Q4	$8K	Hold	95	–	–	﹤0.01%	625
2017 Q3	$8K	Sell	95 -3	-3%	-$238	﹤0.01%	643
2017 Q2	$7K	Hold	98	–	–	﹤0.01%	482
2017 Q1	$6K	Sell	98 -1	-1%	-$66	﹤0.01%	505
2016 Q4	$6K	Buy	+99	New	+$6.25K	﹤0.01%	517

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Cable Hill Partners's LGND Position: Q2 2019 in Review

Cable Hill Partners sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 30 shares — an estimated $2K sold.

Cable Hill Partners first reported a position in LGND in Q4 2016 and held it in 10 quarters. The position peaked at $8K in Q4 2017. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

Cable Hill Partners reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 30 Ligand Pharmaceuticals shares in Q2 2019, an estimated $2K.
Cable Hill Partners first reported a position in Ligand Pharmaceuticals in Q4 2016 and held it in 10 quarters.
Cable Hill Partners's Ligand Pharmaceuticals position peaked at $8K in Q4 2017.
305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.